Safety Profile of Tegaserod, a 5-HT 4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.9, 2004-01, pp. : 619-631

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tegaserod: a new 5-HT4 agonist in the treatment of irritable bowel syndrome

By Tack Jan Corsetti Maura

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 8, 2002-08 ,pp. : 1211-1218

Informa Healthcare

Access to resources Recommend Favorite

The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome

By McLaughlin John Houghton Lesley A

Expert Opinion on Drug Safety, Vol. 5, Iss. 2, 2006-03 ,pp. : 313-327

Informa Healthcare

Access to resources Recommend Favorite

Review of tegaserod in the treatment of irritable bowel syndrome

By Patel Sonal Berrada Driss Lembo Anthony

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 11, 2004-11 ,pp. : 2369-2379

Informa Healthcare

Access to resources Recommend Favorite

Tegaserod effective in irritable bowel syndrome

Inpharma, Vol. 1, Iss. 1313, 2001-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

The Cardiovascular Safety Profile of Renzapride, a Novel Treatment for Irritable Bowel Syndrome

By Meyers NL Hickling RI

The Journal of International Medical Research, Vol. 35, Iss. 6, 2007-11 ,pp. : 848-866

Field House Publishing

Access to resources Recommend Favorite